Product Description: Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer[1][2][4][7].
Applications: Cancer-programmed cell death
Formula: C18H19N3O3S
Citations: Acta Pharmacol Sin. 2023 May 24./Adipocyte. 2021 Dec;10(1):646-657./Adv Sci (Weinh). 2023 Jul 10;e2301088./Am J Physiol Endocrinol Metab. 2024 Apr 3./Am J Cancer Res. 2020 Apr 1;10(4):1182-1193./Antioxidants (Basel). 2024 Nov 24./Aquaculture. 2024 Jan 15, 578, 740081./Biochem Biophys Res Commun. 2020 Mar 26;524(1):70-76./Biochem Biophys Res Commun. 2024 Nov 26./Biochemistry (Moscow). 2021 May;86(5):568-576./Biochim Biophys Acta Mol Cell Biol Lipids . 2020 Aug;1865(8):158711./Biomed Pharmacother. 2020 Sep;129:110356./Biomed Pharmacother. October 2022, 113653./Biomedicines. 2021, 9(6), 677./Bioorg Chem. 7 October 2022, 106191./Bioorgan Med Chem. 15 February 2022, 116615./BMC Gastroenterol. 2025 Jan 20;25(1):22./Br J Pharmacol. 2020 May;177(10):2286-2302./Cancer Cell Int. 2023 Aug 11;23(1):164./Cancer Cell. 2024 May 13;42(5):869-884.e9./Cancer Res. 2022 Apr 15;82(8):1503-1517./Carcinogenesis. 2023 Mar 31;bgad015./Cell Commun Signal. 2023 Sep 30;21(1):268./Cell Death Differ. 2022 Nov 3./Cell Death Dis. 2023 Apr 6;14(4):246./Cell Death Dis. 2023 Dec 8;14(12):810./Cell Death Dis. 2024 Sep 29;15(9):695./Cell Death Dis.2024 May 21;15(5):350./Cell Death Discov. 2022 Apr 30;8(1):236./Cell Metab. 2021 Mar 2;33(3):581-597.e9./Cell Metab. 2023 Dec 5;35(12):2165-2182.e7./Cell Metab. 2023 Sep 7;S1550-4131(23)00304-2./Cell Mol Biol Lett. 2022 Feb 2;27(1):11./Cell Prolif. 2023 Jun 15;e13520./Cell Signal. 2022 Mar 6;110299./Cells. 2022, 11(1), 86./Chem Eng J. 2023 Aug 6, 145212./Chinese Pharmacological Bulletin. 2017, 33(4): 517-521. /Circulation. 2022 Nov 30./CNS Neurosci Ther. 2024 Nov;30(11):e70081./Commun Biol. 2024 Apr 9;7(1):429./Drug Dev Res. 2023 Apr 13./Ecotoxicol Environ Saf. 2022 Jun 15;238:113611./Endocr J. 2021 Oct 29./Environ Int. 2023 Nov 25, 108354./Eur J Med Chem. 2021 Aug 25;225:113807./Eur J Med Chem. 5 February 2022, 114061./Eur J Pharmacol. 2019 Jan 15;843:134-144./Eur J Pharmacol. 2020 Sep 5;882:173300./Eur J Pharmacol. 2022 Jul 31;175175./Eur J Pharmacol. 2023 Oct 12:176113./Food Funct. 2019 Dec 11;10(12):7983-7994./Food Science and Human Wellness. 2023 Nov;12(6);2061-2072./Free Radic Biol Med. 2018 Aug 21;126:259-268. /Front Cell Dev Biol. 2020 Jul 29;8:703./Front Mol Neurosci. 2017 Sep 14;10:293./Front Pharmacol. 2022 Jun 27;13:919202./Front Physiol. 2019 Mar 1;10:165./Front Vet Sci. 2023 Nov 17:10:1277586./hLife. 2024 Mar 2./Immunol Invest. 2021 Apr 8;1-18./Inflamm Res. 2024 Aug 7./Int Immunopharmacol. 2021 Jan;90:107150./iScience. 10 October 2022, 105319./iScience. 2023 Feb 28;26(4):106289./J Biol Chem. 2024 Sep 12:107765./J Cardiovasc Transl Res. 2024 Jul 9./J Cell Mol Med. 2019 Oct;23(10):7029-7042. /J Cell Physiol. 2019 Nov;234(11):20694-20703. /J Ethnopharmacol. 2023 Dec 6:117550./J Exp Clin Cancer Res. 2024 Dec 19;43(1):324./J Exp Med. 2022 May 2;219(5):e20211906./J Physiol Biochem. 2022 May;78(2):377-388./J Therm Biol. 2024 Jul 2:123:103906./J Zhejiang Univ Sci B. 2020 Dec; 21(12): 990–998./Kidney Blood Press Res. 2021 Jul 28;1-12./Life Sci. 2021 Jan 5;119013./Mol Med. 2024 Nov 20;30(1):223./Mol Metab. 2024 Oct 29:102053./Molecules. 2024 Oct 15;29(20):4881./Nat Commun. 2023 Jun 2;14(1):3208./Nat Commun. 2023 May 15;14(1):2779./Ocul Surf. 2024 Oct 10:S1542-0124(24)00108-3./Oxid Med Cell Longev. 2021 Oct 14;2021:5527137./Patent. US20180263995A1./Pharmacol Res. 2020 Mar;153:104679./Phytother Res. 2022 Nov 3./PPAR Res. 2023 Nov 8:2023:6422804./PPAR Res. 28 Sept 2022./PPAR Res. 2019 Jul 1;2019:2715176. /Preprints. 2024 Aug 23./Prog Neuropsychopharmacol Biol Psychiatry. 2023 Mar 25;110758./Redox Biol. 2023 Jun./Ren Fail. 2022 Dec;44(1):2056-2065./Reprod Domest Anim. 2023 Sep 15./Research Square Print. 2022 Aug./Sci Rep. 2024 Apr 30;14(1):9960./Sci Total Environ. 2023 May 16;888:164073./Sci Total Environ. 27 October 2022, 159755./Stem Cell Res Ther. 2024 May 1;15(1):127./Stem Cells Dev. 2022 Sep 21./Theranostics. 2022 Jan 24;12(4):1904-1920./Theranostics. 2022 Nov 7;12(18):7699-7716./Front Mol Biosci. 2022 Feb 4;8:766887./Pharmaceuticals. 2022, 15(9), 1055./Research Square Preprint. 2024 Feb 7.
References: [1]Lehmann JM, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6./[2]Willson TM, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8./[3]Thouennon E, et al. Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J Neurochem. 2015 Aug;134(3):463-70./[4]Majeed Y, et al. Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. Mol Pharmacol. 2011 Jun;79(6):1023-30./[5]Ateyya H, et al. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018 Mar;96(3):215-220./[6]Haoshen Feng, et al. Rosiglitazone ameliorated airway inflammation induced by cigarette smoke via inhibiting the M1 macrophage polarization by activating PPARγ and RXRα. Int Immunopharmacol. 2021 Aug;97:107809. /[7]Zehua Wang, et al. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib. Cancer Chemother Pharmacol. 2020 Feb;85(2):273-284.
CAS Number: 122320-73-4
Molecular Weight: 357.43
Compound Purity: 99.94
Research Area: Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease
Solubility: DMSO : 175 mg/mL (ultrasonic)/Ethanol : 2 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : < 0.1 mg/mL (ultrasonic)
Target: Apoptosis;Autophagy;Ferroptosis;PPAR;TRP Channel
Deutsch
English
